Compare Organon & Co. Common Stock (OGN) vs Powell Industries (POWL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Powell Industries — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Powell Industries trades at $164.99 (market cap $6.18B). The key difference: Powell Industries is the larger of the two by market cap, and Organon & Co. Common Stock pays the higher dividend (0.58%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Powell Industries for 6 Days on average.
| OGN | POWL | |
|---|---|---|
Market Cap | $3.61B | $6.18B |
Volume | 1,808,049 | 1,083,698 |
Sector | Health | Industrials |
52-Week High | $13.81 | $322.05 |
52-Week Low | $5.70 | $94.02 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.03B | $5.55B |
Dividend Yield | 0.58% | 0.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Powell Industries (POWL) trades at $182.79, down 1.4% with bearish technical signals. The company shows strong profitability with 16.49% net margin and 28.25% ROE, though recent quarters missed earnings estimates. Analyst consensus is mixed with 30% buy ratings but a $284 price target suggesting 55% upside. The stock faces near-term pressure from technical weakness despite solid fundamentals and a $2.4 billion backlog supporting future growth.
The investment case balances strong operational performance against technical headwinds. Upside potential exists from backlog conversion and capacity expansion, but risks include execution challenges and market volatility. With valuation metrics elevated (P/E 34.99), successful earnings delivery in upcoming quarters remains critical for sustaining investor confidence and achieving analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Powell Industries
Powell Industries designs and manufactures electrical equipment and engineered solutions for power distribution and control. Its products are used across energy, utility, industrial, and commercial infrastructure.
Read more on POWL →
